Ophirex is rewriting the snakebite playbook.

Here is a problem that sounds like it should already be solved. Every year, somewhere between 1.8 and 2.7 million people are injected with venom by a snake, and roughly 100,000 of them die. Many of the survivors lose fingers, feet, or the use of a limb. The victims are overwhelmingly farmers and children in rural Asia, Africa, and Latin America - people who are far from a hospital, far from a refrigerator, and generally far from anyone's investment thesis. Snakebite is, by the numbers, one of the deadliest neglected diseases on Earth, and the standard treatment for it - antivenom - works more or less the way it did when Albert Calmette was making it in the 1890s: you take antibodies from an animal that has been dosed with venom, you purify them, you keep them cold, and you inject them into a patient at a clinic, hoping you picked the right antivenom for the right snake.

Ophirex, Inc. is a small company in Corte Madera, California, that looked at this and asked a slightly different question. Not "how do we make better antibodies," but "what if the drug were a pill?"

It is worth sitting with why snakebite got neglected in the first place, because the answer is not scientific mystery - it is economics. The World Health Organization only reclassified snakebite envenoming as a priority neglected tropical disease in 2017. The people who die from it tend to be poor, rural, and geographically scattered, which is a polite way of saying they are not a market that pulls research dollars. Antivenom production, meanwhile, is a low-margin, technically fiddly business that several manufacturers have simply exited over the years, occasionally producing regional shortages that make an already grim situation worse. Into that vacuum walks a company arguing that the fix might be a shelf-stable small molecule rather than a better antibody.

A molecule with a past

The company's answer is a compound called varespladib. If you are a drug-development person, the name might ring a faint bell, because varespladib is not new. It was developed years ago by Eli Lilly and later Shionogi as a treatment for other conditions - sepsis, cardiovascular disease - where it never quite delivered the outcomes needed for approval. That is the kind of history that usually ends a molecule's career. It also means the compound has something valuable: an established human safety record, accumulated across earlier trials that Ophirex did not have to pay for.

What varespladib does is block secretory phospholipase A2, or sPLA2 - an enzyme that turns out to be one of the workhorses of snake venom. Venom is a chemical cocktail, and its exact recipe varies wildly from species to species, which is precisely why traditional antivenom has to be snake-specific. But sPLA2 shows up in an estimated 95% of snake venoms. If you can reliably shut it down, you have, at least in principle, a single drug that does something useful against a very broad range of bites. That is the whole bet, and it is a genuinely interesting one: instead of matching the antidote to the snake, you target the one ingredient almost all the snakes share.

The logistics are the innovation

The scientifically elegant part is the enzyme. The part that actually matters for a farmer in Uttar Pradesh is the packaging. Antivenom's problem is not only biology; it is supply chain. It needs cold storage. It needs a trained clinician to administer it intravenously and manage the allergic reactions it can trigger. It needs the patient to physically get to where all of that exists, which after a snakebite can mean hours of travel that the venom does not politely pause for.

Ophirex is designing varespladib to be the opposite of that: temperature-stable, and formulated for oral or injectable use so that treatment can start in minutes, in the field, close to where the bite happened. In venom medicine, time is tissue. Compressing the delay from hours to minutes may end up mattering as much as the molecule itself. It is worth being honest that "a stable pill you take right after a bite" is a logistics claim as much as a pharmacology claim - and logistics, in global health, is frequently the actual innovation.

How do you pay for a cure the market ignores?

Which raises the financing question, because the population that most needs this drug is not, in the crude sense, a lucrative customer base. Ophirex's structural answer is that it is a public benefit corporation - a for-profit legally chartered to weigh its mission alongside returns. In practice that has meant assembling money from sources that almost never sit at the same table. The Wellcome Trust put in $2.6 million in 2020 as part of its snakebite program. The US Army's medical materiel arm awarded a $13.8 million contract in 2022 to develop varespladib for special forces, who have their own reasons to want a field-deployable snakebite treatment. And in January 2023 the company closed a $37 million Series B led by AXA IM Prime's impact fund.

That is a philanthropic funder, a defense department, and an impact investor financing the same pill. Snakebite is one of the rare problems where those interests overlap, and Ophirex has been methodical about standing in the middle of the overlap. It has also stacked its board accordingly, adding Moderna co-founder Derrick Rossi and Curt LaBelle of Global Health Funds alongside its Series B.

The defense angle is worth pausing on, because it is the kind of detail that makes the whole model work. Special forces operate in exactly the environments where snakebite is a genuine operational risk and a hospital is nowhere nearby - which is to say the US Army wants a field-deployable snakebite treatment for the same reason a farmer in rural India needs one. A drug that has to prove itself for soldiers can be developed on a defense budget and, if it works, deployed to the civilian populations who need it most. That is not a coincidence Ophirex stumbled into; it is the point. The reported total funding across all these sources sits somewhere around $53 million, which is modest by biotech standards for a company taking on a disease this size.

The honest part: the data

None of this works if the drug does not. In October 2024, Ophirex published results from its Phase 2 trial, called BRAVO, in BMJ Global Health - the first time varespladib had been used to treat actual human snakebite victims, 95 of them across the United States and India. The headline is mixed in the way real drug development usually is: the trial did not meet its primary endpoints. But in the pre-specified group of patients who started the drug within five hours of being bitten, there were positive signals - lower illness severity over the first week, higher rates of complete recovery, better patient-reported function. And the safety profile held up.

A missed primary endpoint with a real signal in the early-treatment subgroup is not a triumph and it is not a failure; it is data. It points, conveniently or not, at exactly the thesis the company started with - that getting the drug in fast is the whole game. It is the kind of result that keeps a program alive and honest at the same time, and Ophirex has FDA Fast Track designation to keep moving it forward.

The founder, and the dogs

Ophirex was founded in 2015 by Matthew R. Lewin, an expedition physician who ran into the limits of snakebite care the direct way - in the field, where the options run out fast. Early seed money came from friends, family, and, memorably, Jerry Harrison of the Talking Heads. The name itself nods to Ophidia, the snakes.

Ophirex is not the only group chasing next-generation snakebite drugs - academic labs and other Wellcome-backed efforts are exploring monoclonal antibodies and rival small molecules like marimastat, and the incumbent antivenom makers are not going anywhere. But the real competitor is inertia: a century-old standard of care that works well enough, in the places that can afford it, that no one was under commercial pressure to replace it. Displacing "well enough for some" with "good enough for everyone, fast" is a harder sell than it sounds, and it is the sell Ophirex has organized itself around.

There is also a second, quieter market: dogs. The same sPLA2 logic that applies to a person applies to a hunting dog bitten on a trail, and Ophirex is developing a veterinary track alongside the human one. It is a reminder that a broad-spectrum venom inhibitor is, by design, broad - and that a company solving an under-funded human problem can find adjacent markets willing to pay while the bigger mission plays out. Whether varespladib ultimately clears regulators is still an open question. But the shape of the bet is unusually clear: one old molecule, one shared enzyme, one pill, delivered fast, to the people antivenom has always struggled to reach.